Second Sight to Double Patient Enrollment for Argus II Retinal Implant U.S. Clinical Trial

SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight® Medical Products, Inc., the leading developer of retinal prostheses for the blind, announced that the U.S. Food and Drug Administration (FDA) has granted approval for up to 20 people who are blind or who have severely impaired vision due to the genetic eye disease, Retinitis Pigmentosa (RP), to participate in the ArgusTM II Retinal Implant feasibility study in the U.S. Currently, 10 RP volunteers are participating in the U.S. study and an additional 12 RP volunteers are participating in similar studies throughout Europe and Mexico. Dr. Mark Humayun of Doheny Eye Institute at the University of Southern California (USC), will present six-month study results for the first 17 individuals who are enrolled at sites throughout the U.S., Europe and Mexico this week during the Association for Research in Vision and Ophthalmology (ARVO) annual meeting.